Influenza virus vaccine live intranasal (trivalent) - MedImmune

Drug Profile

Influenza virus vaccine live intranasal (trivalent) - MedImmune

Alternative Names: CAIV-T; Fluenz; FluMist; Influenza vaccine live intranasal; Trivalent live attenuated seasonal influenza vaccine - MedImmune

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan
  • Developer AstraZeneca; MedImmune
  • Class Influenza virus vaccines-live; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 30 Jun 2016 Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommends against the use of FluMist®
  • 31 Dec 2012 Launched for Influenza virus infections in European Union (Intranasal)
  • 01 Feb 2012 Launched for Influenza virus infections in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top